Samanta A, Srivastava A. Biologics in the management of pediatric inflammatory bowel disease: When and what to choose. World J Clin Pediatr 2025; 14(1): 100938 [DOI: 10.5409/wjcp.v14.i1.100938]
Corresponding Author of This Article
Anshu Srivastava, MD, Professor, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareily Road, Lucknow 226014, Uttar Pradesh, India. avanianshu@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Pediatr. Mar 9, 2025; 14(1): 100938 Published online Mar 9, 2025. doi: 10.5409/wjcp.v14.i1.100938
Biologics in the management of pediatric inflammatory bowel disease: When and what to choose
Arghya Samanta, Anshu Srivastava
Arghya Samanta, Anshu Srivastava, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India
Author contributions: Samanta A contributed to the literature review of the article and wrote the original manuscript; Srivastava A planning and co-drafting of the original manuscript, critical review and revision of the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Anshu Srivastava, MD, Professor, Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareily Road, Lucknow 226014, Uttar Pradesh, India. avanianshu@yahoo.com
Received: September 2, 2024 Revised: November 14, 2024 Accepted: December 2, 2024 Published online: March 9, 2025 Processing time: 111 Days and 18.4 Hours
Core Tip
Core Tip: Biologics have revolutionized the treatment of pediatric inflammatory bowel disease. The increasing number of biologics (anti-tumor necrosis factor alpha, anti-interleukin 12/23 agents, anti-alpha4beta7 integrin agents) and the arrival of small molecules (Janus kinase inhibitors, sphingosine 1-phosphate-inhibitors), have added to our therapeutic armamentarium. The ultimate objective of therapy is to achieve clinical remission and mucosal healing by providing “personalized therapy” keeping in mind the disease particulars, and selecting the therapy based on the efficacy, cost and safety of the biologics. In this review, we have summarized the recent available literature for guiding the pediatric gastroenterologist about the practical use of biologics and small molecules for children with inflammatory bowel disease.
